AI-Designed mRNA vaccine takes on advanced tumors in first human test

NCT ID NCT07560943

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to check safety and find the right dose, with a secondary look at whether the vaccine can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PAN-NeoVax (an AI-designed mRNA vaccine)
What this could lead to: If successful, this could point toward a new way to train the immune system to fight advanced cancers that have not responded to other treatments.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants. The vaccine may not shrink tumors or may cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma melanoma metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

The West China Hospital
RECRUITING

Chengdu, Sichuan, 646000, China
West China Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.